Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
Naval G DaverParesh VyasSuman KambhampatiMonzr M Al MalkiRichard A LarsonAdam S AschGabriel MannisWanxing Chai-HoTiffany N TanakaTerrence J BradleyDeepa JeyakumarEunice S WangKendra SweetHagop M KantarjianGuillermo Garcia ManeroRami S KomrokjiGuan XingGiridharan RamsinghCamille RenardJoshua F ZeidnerDavid A SallmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
mutations, warranting further evaluation of magrolimab with azacitidine in AML. The phase III randomized ENHANCE-2 (ClinicalTrials.gov identifier: NCT04778397) and ENHANCE-3 (ClinicalTrials.gov identifier: NCT05079230) studies are recruiting frontline patients with AML.